Dr. Jan D. Hirsch is Founding Dean of the University of California Irvine School of Pharmacy and Pharmaceutical Sciences and also Professor of Clinical Pharmacy. She is a Distinguished Scholar and Fellow of the National Academies of Practice (NAP) in Pharmacy, and Distinguished Fellow of the Get the Medications Right (GTMRx) Institute, and joined UC Irvine in January of 2019.
Previously she was Professor of Clinical Pharmacy and Chair of the Division of Clinical Pharmacy at the Skaggs School of Pharmacy and Pharmaceutical Sciences, at the University of California, San Diego. She was also Executive Director of an outreach program of the school providing medication therapy management services in the community. She received her B.S. in Pharmacy and M.S. and Ph.D. degrees in Pharmacy Administration from the University of South Carolina, College of Pharmacy. Prior to returning to academia, she spent 14 years in the pharmaceutical and managed care industries where she was responsible for establishing and managing outcomes research departments for two pharmaceutical companies (Glaxo Group Research in Greenford (UK) and Allergan (US)) and a pharmacy benefit management company (Prescription Solutions (US)).
Dr. Hirsch's research interests are focused in the areas of pharmacoeconomics and outcomes research. Specifically, i) assessing the full value (economic, clinical and humanistic) of pharmacy services and pharmaceuticals and ii) integrating patient reported outcomes (PRO's) [e.g. Health Related Quality of Life (HRQOL)] into pharmaceutical and medical practice to improve patient management.
She has served as PI or Co-PI for many studies evaluating the clinical, economic and humanistic outcomes for patients receiving novel pharmacy services for diabetes, hypertension, mental health, and HIV/AIDS. This research has been recognized by state and federal agencies, professional pharmacy organizations and the interdisciplinary National Academies of Practice. Dr. Hirsch has also been the PI for studies creating and/or validating four HRQOL instruments [Functional Living Index Emesis (FLIE), Ocular Surface Disease Index (OSDI), Gout Impact Scale (GIS), Heart Transplant Treatment Burden Questionnaire (HTBQ)] and a method for measuring medication regimen complexity (MRCI). Each of these has been an important contribution to clinical practice and research as evidenced by their uptake by other researchers and inclusion in more than 100 clinical trials.
Areas of Expertise (9)
Comprehensive Medication Management (CMM)
Medication Therapy Management
Gout Impact Scale
Health Related Quality of Life
Distinguished Scholar and Fellow National Academies of Practice in Pharmacy (NAP) (professional)
2018 Distinguished Scholar and Fellows have an exemplary career of ten years or more, and are committed to interprofessional practice and accessible, affordable healthcare for all. Fellows are judged by distinguished peers to have made significant and ongoing contributions in their profession. Distinguished Scholar and Fellows have made notable academic achievements such as significant and enduring educational and/or research contribution to practice.
Distinguished Fellow of Get the Medications Right Institute (GTMRx) (professional)
2019 The GTMRx Distinguished Fellows program celebrates the exceptional contributions of those advancing our ability to enhance life by ensuring appropriate and personalized use of medication and gene therapies. Distinguished Fellows drive innovation, policy, and work alongside like-minded national leaders to advance evidence, best practices, and ideas to accelerate the transformation to a team-based, person-centered approach to comprehensive medication management.
Excellence in Teaching Award (professional)
Distinguished Alumni Award (professional)
2002 University of South Carolina College of Pharmacy
University of South Carolina: MS, Pharmacy Administration 1982
University of South Carolina: Ph.D., Pharmacy Administration 1986
University of South Carolina: BS, Pharmacy 1980
- American Pharmaceutical Association (APhA)
- Academy of Managed Care Pharmacy (AMCP)
- American Association of Colleges of Pharmacy (AACP)
- California Pharmacists Association (CPhA)
- National Academies of Practice (NAP)
- Applied Pharmacoeconomics and Outcomes Research Forum
- Get the Medications Right (GTMRx) Institute
Media Appearances (6)
New faculty faces
UCI News online
Jan Hirsch, director and founding dean of UCI’s planned School of Pharmacy & Pharmaceutical Sciences, who is an acclaimed researcher, pharmacist and organizational leader with experience in bridging academics, scholarship and clinical practice in the private and public sectors;
Founding dean of planned UCI pharmacy school comes aboard in January
Daily Pilot online
UC Irvine will bring on researcher and pharmacist Jan Hirsch to oversee the planning of a new pharmacy school.
Hirsch to Head New UCI Pharmacy School
HME Business online
The University of California, Irvine (UCI) has selected Dr. Jan Hirsch as director and founding dean of the planned School of Pharmacy & Pharmaceutical Sciences.
Jan Hirsch named founding dean of planned School of Pharmacy & Pharmaceutical Sciences
UCI News online
Jan Hirsch, Ph.D. – an acclaimed researcher, pharmacist and organizational leader – has been selected as director and founding dean of the planned School of Pharmacy & Pharmaceutical Sciences at the University of California, Irvine.
Inaccurate Prescriptions, Usage Costs US $528.5 Billion Annually: UCSD Study
NBC San Diego online
Medical problems and death resulting from prescriptions inaccurately prescribed or taken, costs an average of $528.5 billion annually – 16 percent of the total U.S. healthcare budget in 2016 – according to a research study at the Skaggs School of Pharmacy at the University of California San Diego. Non-optimized medications, as they’re called, are an increasing problem that can cause new health problems or even death. Researchers gave the example of a patient with the flu failing to fill a prescription and later ending up in the emergency room with more serious symptoms, costing the patient, hospital and the insurance company.
When drugs are wrong, skipped or make you sick: The cost of non-optimized medications
Science Daily online
Watanabe led the study with Jan Hirsch, PhD, professor of clinical pharmacy and chair of the Division of Clinical Pharmacy at Skaggs School of Pharmacy, and Terry McInnis, MD, of Laboratory Corporation of America and the Get the Medications Right Institute.
Preferred Pronouns (1)
She, Her, Hers
Research Focus (2)
Gout disease-specific quality of life and the association with gout characteristics
Assess the association of gout characteristics with health-related quality of life (HRQoL) using a new gout-specific HRQoL instrument, the Gout Impact Scale (GIS).
Evaluation of an Instrument Assessing Influence of Gout on Health-Related Quality of Life
The study was conducted to evaluate the reliability and validity of an instrument assessing the influence of gout (acute and chronic) on health-related quality of life (HRQOL).
Research Grants (8)
Assessment of Stakeholder Perspectives of the Clinical Utility of Pharmacogenomics in Solid Organ Transplantation
Skaggs Scholar Program $67,514
The focus of the study is to assess stakeholder perspectives regarding the clinical utility of pharmacogenomic (PGx) testing following kidney, liver, and heart transplantation. The study conducted by individual semi-structured interviews and focus groups with kidney, liver, and heart transplantation patients and providers.
Reducing Hospital Utilization (Readmissions and ED) Community Pharmacist Medication Reconciliation Program
United Healthcare $227,405
A longitudinal study seeking to reduce hospital reutilization (readmission and ER utilization) by adding community pharmacists to the care team. The objective of the study is to conduct and evaluate implementation of a community pharmacy based transitions of care program (PharmD_TOC)for high-risk post-discharge patients. The study runs from September 2016 to January 2021.
Multidimensional Efficacy of Canukinumab vs. Triamcinolone for Gouty Arthritis Treatment
Novartis Pharmaceuticals $50,000
Canakinumab (CAN), a selective, fully human, anti-IL-1β monoclonal antibody, may be a potential therapeutic option for treating acute gout attacks and delaying new attacks in these patients (pts). Efficacy and safety of canakinumab was previously demonstrated in two 12-week, multicenter, double-blind, double dummy, active controlled trials (β-RELIEVED [N=228]; β-RELIEVED II [N=226]).1 Health-related quality of life was also measured in these studies, but not all patients completed each questionnaire. Therefore, a composite health outcomes response endpoint was developed to better interpret each patient’s overall response to treatment.
Medication Regimen Complexity Methods and Measurement in Defined Clinical Populations
Skaggs Scholars Program $88,000
An investigation of medication regimen complexity in four disease areas (hypertension, diabetes, geriatric depression and HIV), and additional measures of medication risk that should also be included in assessing the “complexity” of medication regimens in these patient populations, as a method of identifying patients who may benefit most from pharmacist intervention.
Pilot Project for Medication Therapy Management (MTM) – PharmD/MD Collaborative Practice in Primary Care.
National Institutes of Health (NIH) - National Heart, Lung and Blood (NHLBI - 1RC2HL101811-01) $573,215
A randomized, pragmatic, clinical trial of hypertensive patients randomly selected to receive care from a pharmacist within a PharmD-MD Collaborative Practice team in a university primary care clinic.
A pilot study of a pharmacist-led Medication Therapy Management Services (MTMS) in Mental Health Clinic
California Department of Healthcare Services $52,487
Challenges and opportunities associated with needs assessment, implementation, and reimbursement of a psychiatric pharmacist medication therapy management (MTM) clinic.
Validation of the Gout Assessment Questionnaire (GAQ) in a non-clinical trial population.
TAP Pharmaceuticals $195,867
The objectives of this study were to further the development of a gout-specific quality of life instrument to enhance its use in clinical practice and to evaluate the psychometric properties of the new Gout Assessment Questionnaire (GAQ2.0) in a large community-based population.
Gout Impact (GI of GAQ2.0) Responsiveness and Minimal Important Difference Evaluation
TAP Pharmaceuticals $87,500
A longitudinal study of gout patients investigating the responsiveness and minimal important difference (MID) of the GAQ2.0 to aid interpretation of results when the instrument is used in clinical trials or clinical practice to monitor change in gout status.
National survey of physicians’ perspectives on pharmacogenetic testing in solid organ transplantation. Clinical Transplantation.PubMed
KM Deininger, SM Tsunoda, JD Hirsch, HD Anderson, YM Lee, CK McIlvennan, RL Page, JN Tran, CL Aquilante
Local pharmacies can reduce the dual risks of COVID19 and influenza this fall. Now is the time to prepare.The Hill
JH Watanabe and JD Hirsch
PaCIR: A Tool to Enhance Pharmacist Patient Care Intervention ReportingJournal of the American Pharmacists Association
PG Clay, AL Burns, BJ Isetts, JD Hirsch, MA Kliethermes, LG Planas
Patterns of Stress, Coping and Health-Related Quality of Life in Doctor of Pharmacy StudentsAmerican Journal of Pharmaceutical Education
JD Hirsch, P Nemlekar, P Phuong, KA Hollenbach, KC Lee, DS Adler and CM Morello
2020 To examine perceived stress, coping strategies, and health-related quality of life in Doctor of Pharmacy students across the first three years (pre-clinical portion) of the curriculum.
Improved glycemic control outcomes regardless of mental health disorders in a pharmacist-endocrinologist diabetes intense medical management (DIMM) “tune up” clinic.Annals of Pharmacotherapy
CM Morello, T Nguyen, L Tao, JD Hirsch
Advancing Pharmacist Collaborative Care within Academic Health SystemsPharmacy
L Awdishu, R Singh, I Saunders, J Hirsch, S Lorentz, R Atayee, J Ma, S Tsunoda, J Namba, C Mnatzaganian, N Painter, J Watanabe, F Yam, K Lee, C Daniels, C Morello
Evaluation of a Short, Interactive Diabetes Self-Management Program by Pharmacists for Type 2 DiabetesBMC Research Notes
RF Singh, P Kelly, A Tam, J Bronner, CM Morello, JD Hirsch
Federal and Patient Spending on Ten Most Expensive Medications in Medicare Part D from 2011 to 2015Journal of the American Geriatrics Society
JH Watanabe, JD Hirsch
Estimated Cost-Effectiveness, Cost Benefit, and Risk Reduction Associated with an Endocrinologist-Pharmacist Diabetes Intense Medical Management “Tune-Up” ClinicJournal of Managed Care & Specialty Pharmacy
Hirsch et al
2017 In 2012 U.S. diabetes costs were estimated to be $245 billion, with $176 billion related to direct diabetes treatment and associated complications. Although a few studies have reported positive glycemic and economic benefits for diabetes patients treated under primary care physician (PCP)-pharmacist collaborative practice models, no studies have evaluated the cost-effectiveness of an endocrinologist-pharmacist collaborative practice model treating complex diabetes patients versus usual PCP care for similar patients.
Cost of Prescription Drug-Related Morbidity and MortalityAnnals of Pharmacotherapy
JH Watanabe, T McInnis, JD Hirsch
Economic Impact of and Treatment Options for Type 2 DiabetesAmerican Journal of Managed Care
JD Hirsch, CM Morello
Estimated Cost-Effectiveness, Cost-Benefit, and Risk Reduction Associated with a Pharmacist-Endocrinologist Diabetes Intense Medical Management “Tune Up” Clinic.Journal of Managed Care and Specialty Pharmacy
JD Hirsch, M Bounthavong, A Arjmand, DR Ha, CL Cadiz, A Zimmerman, H Ourth, AP Morreale, SV Edelman, CM Morello
Strategies for Addressing the Cost of Nonadherence in DiabetesAmerican Journal of Managed Care
CM Morello, JD Hirsch
Student Pharmacists' Perceptions of ImmunizationsCurrents in Pharmacy Teaching and Learning
K Kubli, S McBane, JD Hirsch, S Lorentz
Clinical Outcomes Associated With a Collaborative Pharmacist-Endocrinologist Diabetes Intense Medical Management “Tune Up” Clinic in Complex PatientsAnnals of Pharmacotherapy
CM Morello, MLD Christopher, L Ortega, J Khoan, T Rotunno, SV Edelman, RR Henry, JD Hirsch
Primary Care–based, Pharmacist–physician Collaborative Medication-therapy Management of Hypertension: A Randomized, Pragmatic TrialClinical Therapeutics
Hirsch et al
2014 A collaborative pharmacist–primary care provider (PharmD-PCP) team approach to medication-therapy management (MTM), with pharmacists initiating and changing medications at separate office visits, holds promise for the cost-effective management of hypertension, but has not been evaluated in many systematic trials. The primary objective of this study was to examine blood pressure (BP) control in hypertensive patients managed by a newly formed PharmD-PCP MTM team versus usual care in a university-based primary care clinic.
Changes in medication regimen complexity and the risk for 90-day hospital readmission and/or emergency department visits in U.S. Veterans with heart failureRes Social Adm Pharm
FK Yam, T Lew, SA Eraly, WI Hsiang, JD Hirsch, MJ Devor
Validation of a Patient‐Level Medication Regimen Complexity Index as a Possible Tool to Identify Patients for Medication Therapy Management InterventionPharmacotherapy
Jan D. Hirsch, Kelli R. Metz, Patrick W Hosokawa, Anne M. Libby et al
2014 The Medication Regimen Complexity Index (MRCI ) is a 65‐item instrument that can be used to quantify medication regimen complexity at the patient level, capturing all prescribed and over‐the‐counter medications. Although the MRCI has been used in several studies, the narrow scope of the initial validation limits application at a population or clinical practice level.
A Composite Endpoint Measure to Consolidate Multidimensional Impact of Treatment on Gouty ArthritisOpen Journal of Rheumatology and Autoimmune Diseases
AJ Sarkin, A Gnanasakthy, RS Lale, KJ Choi, JD Hirsch
Efficacy of Canakinumab vs. triamcinolone acetonide according to multiple gouty arthritis‐related health outcomes measuresInternational Journal of Clinical Practice
JD Hirsch, A Gnanasakthy, R Lale, K Choi, AJ Sarkin
2014 Canakinumab (CAN ), a selective, fully human, anti‐IL ‐1β monoclonal antibody, has demonstrated long‐term benefits in gouty arthritis (GA ) patients, who have contraindications for, or are unresponsive or intolerant of, non‐steroidal anti‐inflammatory drugs (NSAID s) or colchicine (two trials:β‐RELIEVED [n = 228]; β‐RELIEVED II [n = 226]). The trials collected different responses, including patient‐reported outcomes (PRO ). A composite response end‐point (CRE ) was used to interpret each patient's overall response to treatment.
Navigating complex patients using an innovative tool: The MTM Spider WebJournal of American Pharmacists Association
CM Morello, JD Hirsch, KC Lee.
Patient-level medication regimen complexity in older adults with depressionClinical Therapeutics
SA Linnebur, JP Vande Griend, KR Metz, PW Hosokawa, JD Hirsch, AM Libby
Development of a Pharmacist-Psychiatrist Collaborative Medication Therapy Management (MTM) ClinicJournal of the American Pharmacists Association
KB Tallian, JD Hirsch, GM Kuo, C Chang, T Gilmer, M Messinger, P Chan, CE Daniels, KC Lee
Documenting and Describing the Value of Medication Therapy Management Services (MTMS) and Outcomes in Community Pharmacy: Methods and Case StudyCalifornia Pharmacist
JD Hirsch, KC Lee, CM Morello
Patient-Level Medication Regimen Complexity Across Populations with Chronic DiseaseClinical Therapeutics
AM Libby, DN Fish, PW Hosokawa, SA Linnebur, KR Metz, KV Nair, JJ Saseen, JP Vande Griend, SP Vu, JD Hirsch
Antiretroviral Therapy Adherence, Medication Use, and Health Care Costs During 3 Years of a Community Pharmacy Medication Therapy Management Program for Medi-Cal Beneficiaries with HIV/AIDSJournal of Managed Care Pharmacy
J D Hirsch, M Gonzales, A Rosenquist, TA Miller, TP Gilmer, BM Best
Minimally Important Differences of the Gout Impact Scale in a Randomized Controlled TrialRheumatology (Oxford)
D Khanna, AJ Sarkin, MM Shieh, AF Kavanaugh, RA Terkeltaub, SJ Lee, JA Singh, JD Hirsch
Health Care Utilization in Patients with Gout.Seminars in Arthritis and Rheumatism
JA Singh, A Sarkin , M Shieh, D Khanna, R Terkeltaub, SJ Lee, A Kavanaugh, JD Hirsch
Impact of Gout on Health Related Quality of Life and the Relationship to Gout CharacteristicsPatient Related Outcome Measures
JD Hirsch, R Terkeltaub, D Khanna, J Singh, A Sarkin, M Shieh, A Kavanaugh, SJ Lee
Medication Therapy Management Services in Community Pharmacy: A Pilot Program in HIV Specialty PharmaciesJournal of Evaluation in Clinical Practice
A Rosenquist, BM Best, TA Miller, TP Gilmer, JD Hirsch
Pharmacists as Immunizers: A California SurveyCalifornia Pharmacist
J Fontanesi, JD Hirsch, S Lorentz, J Rybar
Predictors of Doctor-Rated and Patient-Rated Gout Severity: Gout Impact Scales Improve AssessmentJournal of Evaluation in Clinical Practice
AJ Sarkin, AE Levack, MM Sheih, AF Kavanaugh, D Khanna, JA Singh, RA Terkeltaub, SJ Lee, JD Hirsch
Comparison of Pharmacists and Primary Care Providers as ImmunizersThe American Journal of Pharmacy Benefits
J Fontanesi, JD Hirsch, Lorentz S, Rybar, D Bowers, J Shafrin
Students’ Health-Related Quality of Life Across the Preclinical Pharmacy CurriculumAmerican Journal of Pharmaceutical Education
JD Hirsch, AH Do, AS Manoguerra, D Adler
Evaluation of an Instrument Assessing Gout Impact on Health-Related Quality of LifeJournal of Rheumatology
JD Hirsch, SJ Lee, R Terkeltaub, D Khanna, J Singh, A Sarkin, J Harvey, A Kavanaugh
Evaluation of the first year of a pilot program in community pharmacy: HIV/AIDS medication therapy management for Medi-Cal beneficiariesJournal of Managed Care Pharmacy
JD Hirsch, A Rosenquist, BM Best, TA Miller, TP Gilmer
Patient request for pharmacist counseling and satisfaction: Automated prescription delivery system vs. regular pick-up counterJournal of the American Pharmacists Association
JD Hirsch, A Oen, S Robertson, N Nguyen, C Daniels